PROCEPT BioRobotics Corporation
PRCT · Price history
Price at last available close
$20.20
+$2.95 (+17.10%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About PROCEPT BioRobotics Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH).
How they make money
PROCEPT BioRobotics operates a recurring revenue model by selling the AquaBeam Robotic System as capital equipment to hospitals and clinics. The company generates ongoing revenue through the sale of single-use handpieces required for each patient procedure and by providing post-warranty service contracts for the installed robotic systems.
Products & services
The company develops and markets the AquaBeam Robotic System, a surgical robotics platform used for the treatment of benign prostatic hyperplasia (BPH) through a procedure known as Aquablation therapy.
Brands & revenue mix
The primary robotic platform for Aquablation therapy.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of components and assembly of the AquaBeam Robotic System.Source
Competitors
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
32
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
54
Fair
Financial Strength
56
Business Quality / Moat
83
Management
40
Growth Quality
40
Risk / Durability
23
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
41
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
54/100
Building Historical Record
Model Score 54/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for PRCT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can PRCT maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can PRCT fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PRCT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PRCT to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PRCT's current valuation?
Essential Investment Snapshot
Wall Street Score
32
Opportunity Score
41
Market Cap
$1.15B
P/E Ratio
-9.0
EPS
$-1.94
52-Week High
$38.11
52-Week Low
$16.66
Beta
0.92
Analyst Target
$21.00
Shares Outstanding
55.5M
Total Revenue
$337.3M
Total Debt
$77.5M
Dividend
No current dividend
Liquidation Value / Share
$6.12
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for PRCT
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-29.0x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on PRCT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Aquablation technology.
- +Recurring revenue business model.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on third-party manufacturers.
- −Regulatory approval and reimbursement uncertainty.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
32
Oct 1, 2026
Change
Unchanged
Current Score
32
Oct 15, 2026
Category Changes
PRCT score was unchanged.
Projected Score
Projected Score
38
Projected Change
+5.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$20.20
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $337.3M | $308.1M | $224.5M | $136.2M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $122.3M | $111.8M | $87.4M | $65.1M | ···· | ···· | ···· | ···· |
| Gross Profit | $215.0M | $196.2M | $137.1M | $71.0M | ···· | ···· | ···· | ···· |
| Research & Development | $77.2M | $71.3M | $62.3M | $48.4M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $252.1M | $228.8M | $171.4M | $131.8M | ···· | ···· | ···· | ···· |
| Operating Expenses | $329.3M | $300.1M | $233.7M | $180.2M | ···· | ···· | ···· | ···· |
| EBITDA | -$98.9M | -$85.4M | -$82.0M | -$98.1M | ···· | ···· | ···· | ···· |
| Operating Income | -$114.2M | -$103.9M | -$96.6M | -$109.2M | ···· | ···· | ···· | ···· |
| Interest Expense | $3.5M | $3.6M | $4.2M | $4.0M | ···· | ···· | ···· | ···· |
| Income Before Tax | -$109.5M | -$95.4M | -$91.4M | -$105.9M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $284K | $190K | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Net Income | -$109.8M | -$95.6M | -$91.4M | -$105.9M | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.94 | $-1.72 | $-1.75 | $-2.24 | ···· | ···· | ···· | ···· |
| Basic Shares | 56.51M | 55.54M | 52.13M | 47.26M | ···· | ···· | ···· | ···· |
| Diluted Shares | 56.51M | 55.54M | 52.13M | 47.26M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$94.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.47
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-2.4%
Cash Change
-24.7%
Margin Change
-3.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels. Pressure indicators included cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 19.3%. EPS increased 34.3%. Cash declined 24.7%. Total debt declined 2.4%. Net income margin declined by 3.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation
LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation
Rumor Mill · PRCT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial